196 indexable Biopharma Outsourcing companies headquartered in New Jersey, United States, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $1.7B across 29 funded companies.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
Kashiv BioSciences
Developer of biosimilar medicines |
$222.3M | — | Acquired | Conventional Debt Dec 2025 | 235 | 2010 | ↑ Active |
| 2 |
Tharimmune
Clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions |
$2.1M | — | Public | Post IPO Nov 2025 | 1 | 2023 | ↑ Active |
| 3 |
Inaedis
Provider of biological drugs research and development services |
$3.1M | — | Funding Raised | Grant (prize money) Jun 2025 | — | 2022 | ↑ Active |
| 4 |
Experic
Provider of supplychain and packaging solutions for biopharma sector |
$24M | — | Series B | Series B Sep 2024 | 51 | 2019 | ↑ Active |
| 5 |
Ascendia Pharmaceutical Solutions
CDMO providing formulation development, analytical, and manufacturing services for pharmaceutical and biological companies |
$2.5M | — | Seed | Seed May 2025 | — | 2012 | ↑ Active |
| 6 |
Evergreen Theragnostics
Provider of radiopharmaceuticals manufacturing and regulatory services |
$75.5M | — | Acquired | Series C Apr 2024 | 55 | 2019 | — |
| 7 |
GenScript ProBio
Provider of antibody discovery, bioanalytic, and contract based clinical plasmid manufacturing services |
$411M | — | Series C | Series C Jan 2023 | 177 | 2002 | — |
| 8 |
BioCentriq
CDMO focused on cell and gene therapy based drug developmet |
$29.2M | — | Acquired | Series A Jan 2024 | 75 | 2019 | — |
| 9 |
Indegene
Suite solutions for payers and healthcare providers |
$220M | $598.6M as of 2021 |
Public | Series C Apr 2021 | 350 | 1998 | — |
| 10 |
Covance
Lab R&D drug testing for biopharma, advancing therapeutic development |
$250.3M | — | Acquired | Grant (prize money) Mar 2021 | 10,718 | 1996 | — |
| 11 |
CCM Bio
Develops novel drugs, companion diagnostics, and offers contract research, development, and manufacturing. |
$25M | — | Series A | Series A Aug 2023 | — | 2021 | — |
| 12 |
Catalent
Provider of development, manufacturing, and packaging solutions for medicines and supplements |
$202.4M | — | Acquired | Grant (prize money) Oct 2020 | 1,900 | 2007 | — |
| 13 |
Conjupro Biotherapeutics
Biopharmaceutical company offering diversified research and development solutions |
$9.3M | — | Series A | Series A Sep 2023 | 18 | 2017 | — |
| 14 |
Diligent
Provider of contract based clinical trial and quality management services |
$8.3M | — | Series A | Series A May 2023 | 24 | 2018 | — |
| 15 |
Celgene
Developer of therapies for treating cancer and inflammatory diseases |
$45M | — | Acquired | Post IPO Feb 2018 | 4,891 | 1986 | — |
| 16 |
Champion Oncology
Oncology CRO providing preclinical and clinical research services globally |
$36.8M | — | Public | Post IPO Mar 2015 | 230 | 1985 | — |
| 17 |
NPS Pharma
Global pharmaceutical company committed to better health and a brighter future |
$50M | — | Acquired | PE Aug 2014 | 365 | 1986 | — |
| 18 |
okCapsule
Provider of personalized supplement manufacturing and supply chain solutions |
$9.5M | — | Series A | Series A Mar 2022 | 19 | 2019 | — |
| 19 |
Delsys Pharmaceutical Corporation
Technology for pharmaceutical formulation development, manufacture and drug delivery |
$40M | — | Acquired | Apr 2000 | — | 1977 | — |
| 20 |
Orthobond
Functionalized anti-microbial surface coatings for medical devices |
$3.4M | — | Series A | Series A Sep 2022 | 16 | 2004 | — |
| 21 |
Longevica
Provider of research, clinical studies, technology, and development of drugs |
$2.7M | — | Seed | Seed Sep 2022 | — | 2009 | — |
| 22 |
Halo Pharma
CDMO offering integrated drug development services |
$25M | — | Acquired | PE Jan 2015 | 450 | 2006 | — |
| 23 |
Laureate Biopharmaceutical Services
Biologics CDMO, now a part of Patheon/Thermo Fisher |
$20M | — | Acquired | Series A Jan 2011 | 106 | 1981 | — |
| 24 |
Guardian Drug
Manufacturer of over-the-counter pharmaceutical and nutritional products |
$10M | — | Series A | Series A Feb 2018 | 87 | 1984 | — |
| 25 |
Appco Pharma
US-based pharmaceutical company specializing in drug development, manufacturing, and commercialization |
$5M | — | Funding Raised | Conventional Debt Mar 2020 | 123 | 2014 | — |
| 26 |
Soterius
Provider of pharmacovigilance, medical affairs, and regulatory services for pharma |
$1.5M | — | Series A | Series A Mar 2020 | 38 | 2018 | — |
| 27 |
ERG
Provider of clinical research site services |
$1M | — | Acquired | Unattributed May 2015 | 259 | 1998 | — |
| 28 |
Apicore
Traditional company offering contract manufacturing and custom synthesis services |
$720.1K | — | Acquired | Series A Oct 2016 | 56 | 2003 | — |
| 29 |
Provid Pharmaceuticals
Developing MHC inhibition drugs for multiple sclerosis and autoimmune diseases |
$400.2K | — | Funding Raised | Grant (prize money) Aug 2014 | 5 | 2001 | — |
| 30 |
Prince Sterilization
Contract sterilization services and sterile ready-to-use components for pharmaceutical and medical devices |
— | — | Late Stage | PE Nov 2024 | 30 | 2017 | ↑ Active |
| 31 |
Sannova
CRO focused on clinical research, bio analytical, phase I-IV, and pre clinical services |
— | — | Seed | Seed Aug 2022 | 50 | 2006 | — |
| 32 |
Nutra-Med Packaging
Provider of drugs packaging services |
— | — | Late Stage | PE Feb 2022 | 500 | 1999 | — |
| 33 |
SSI Strategy
Strategic partner for biotech companies, from concept to commercialization |
— | — | Acquired | PE Dec 2020 | 90 | 2010 | — |
| 34 |
Steri-Pharma
Manufacturer and wholesaler of roofing sheets and turbine roof ventilators |
— | — | Late Stage | PE Jan 2019 | 67 | 2002 | — |
| 35 |
Evolution Research Group
Clinical research organization conducting trials for various medical conditions and healthy volunteers |
— | — | Acquired | Conventional Debt Jun 2018 | — | 2015 | — |
| 36 |
Aucta Pharmaceuticals
Innovating enhanced therapeutics using technology for specialty brand and generic products |
— | — | Seed | Seed Nov 2015 | 35 | 2012 | — |
| 37 |
Clinical Research Laboratories
Safety and efficacy testing for cosmetic, personal care, and pharmaceutical products |
— | — | Acquired | PE Dec 2014 | 75 | 1992 | — |
| 38 |
Global Clinical Trials
Global CRO providing clinical research services for biotech, pharma, and medical devices |
— | — | Funding Raised | Grant (prize money) Nov 2011 | 93 | 2001 | — |
| 39 |
Clinpro
Clinical service provider for Phase II-IV clinical trials |
— | — | Late Stage | Nov 2008 | — | 1998 | — |
| 40 |
CRI Lifetree
Clinical research and drug trial services specializing in CNS diseases. |
— | — | Acquired | PE Oct 2007 | 250 | 1998 | — |
| 41 |
3 Infotek
Provider of software validation and regulatory consulting services |
— | — | Unfunded | — | 119 | 2003 | — |
| 42 |
4C Pharma
Comprehensive healthcare solutions ensuring safety, compliance, and efficiency in pharmaceutical operations |
— | — | Unfunded | — | 92 | 2014 | — |
| 43 |
Abon Pharma
Provider of specialty generics with high formulation barriers |
— | — | Unfunded | — | 63 | 2009 | — |
| 44 |
Accurant
CRO providing GLP bioanalysis, CMC testing, clinical trial and regulatory services to clients in pharmaceuticals sectors |
— | — | Unfunded | — | 23 | 2017 | — |
| 45 |
Adare Pharma Solutions
CDMO manufacturing solid drugs |
— | — | Acquired | — | 217 | 2015 | — |
| 46 |
Admix Pharma
Provider of contract testing and product development services for pharmaceuticals |
— | — | Unfunded | — | 5 | 2000 | — |
| 47 |
Agno Pharma
CDMO offering services from drug discovery to manufacturing |
— | — | Unfunded | — | 4 | 2003 | — |
| 48 |
Akara
Provider of market research, regulatory, and consulting services to biopharma sector |
— | — | Acquired | — | — | 2000 | — |
| 49 |
alligent group
Alligent develops and delivers integrated aligned medical affairs solutions from strategy |
— | — | Acquired | — | 30 | 2010 | — |
| 50 |
APCER Life Sciences
Provider of quality assurance and regulatory consulting services |
— | — | Unfunded | — | 350 | 2007 | — |
Developer of biosimilar medicines. It is an integrated biopharmaceutical company with capabilities in R&D, clinical, manufacturing, regulatory, and intellectual property.
Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing therapeutic candidates for rare, inflammatory, and oncologic conditions. They are dedicated to improving the lives of patients through their portfolio of innovative treatments.
Provider of biological drugs research and development services
Provider of supplychain and packaging solutions for biopharma sector
CDMO providing formulation development, analytical, and manufacturing services for pharmaceutical and biological companies. It offers customized formulations, analytical services, and GMP/cGMP manufacturing for clinical trial materials. The company specializes in nanotechnologies to address solubility challenges and develop pharmaceutical products. It provides services for small molecules, biologics, and gene deliver
Provider of radiopharmaceuticals manufacturing and regulatory services
Provider of antibody discovery, bioanalytic, and contract based clinical plasmid manufacturing services
CDMO focused on cell and gene therapy based drug developmet
Suite solutions for payers and healthcare providers. The payer solutions portfolio includes transformation, care management, member acquisition and engagement, healthcare analytics, and medicare analysis; and the ACO solutions portfolio comprises transformation services, outcomes improvement, patient engagement, and analytics. It also operates cloud-based platforms for customer engagement, member loyalty & retention,
Lab R&D drug testing for biopharma, advancing therapeutic development. They navigate the complexities of drug development with scientific laboratory services. They offer solutions that inform every development phase and support targeted therapeutic indications, including emerging treatment modalities. Services include nonclinical development with toxicology, pharmacology, and metabolism expertise, central lab service
Develops novel drugs, companion diagnostics, and offers contract research, development, and manufacturing. The company discovers and develops small molecules, gene therapies, biologics, and nanomedicines. It supports preclinical drug development and Chemistry, Manufacturing and Control (CMC) during trials through its in-house contract research, development, and manufacturing organization. The company also develops co
Provider of development, manufacturing, and packaging solutions for medicines and supplements. It offers services for oral dose forms, biologics, and specialty technologies. These services include formulation, bioavailability enhancement, and analytical solutions. The company also provides clinical supply forecasting, packaging, and distribution.
HHS
Europa
1315 Capital
180 Degree Capital
3LB Seed Capital
7RIDGE
ARK Investment Management
A
Aarabhipartnersconsultants
Aisling Capital
AlpInvest Partners
America’s Seed Fund
Ampersand Capital
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-19.
_1571307202040.png){kind=logo}
.png1508828634522){kind=logo}
